Cargando…

Lacticaseibacillus rhamnosus ATCC 53103 and Limosilactobacillus reuteri ATCC 53608 Synergistically Boost Butyrate Levels upon Tributyrin Administration Ex Vivo

Modulation of the gut microbiota is a trending strategy to improve health. While butyrate has been identified as a key health-related microbial metabolite, managing its supply to the host remains challenging. Therefore, this study investigated the potential to manage butyrate supply via tributyrin o...

Descripción completa

Detalles Bibliográficos
Autores principales: Van den Abbeele, Pieter, Goggans, Mallory, Deyaert, Stef, Baudot, Aurélien, Van de Vliet, Michiel, Calatayud Arroyo, Marta, Lelah, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054277/
https://www.ncbi.nlm.nih.gov/pubmed/36982942
http://dx.doi.org/10.3390/ijms24065859
_version_ 1785015632463396864
author Van den Abbeele, Pieter
Goggans, Mallory
Deyaert, Stef
Baudot, Aurélien
Van de Vliet, Michiel
Calatayud Arroyo, Marta
Lelah, Michael
author_facet Van den Abbeele, Pieter
Goggans, Mallory
Deyaert, Stef
Baudot, Aurélien
Van de Vliet, Michiel
Calatayud Arroyo, Marta
Lelah, Michael
author_sort Van den Abbeele, Pieter
collection PubMed
description Modulation of the gut microbiota is a trending strategy to improve health. While butyrate has been identified as a key health-related microbial metabolite, managing its supply to the host remains challenging. Therefore, this study investigated the potential to manage butyrate supply via tributyrin oil supplementation (TB; glycerol with three butyrate molecules) using the ex vivo SIFR(®) (Systemic Intestinal Fermentation Research) technology, a highly reproducible, in vivo predictive gut model that accurately preserves in vivo-derived microbiota and enables addressing interpersonal differences. Dosing 1 g TB/L significantly increased butyrate with 4.1 (±0.3) mM, corresponding with 83 ± 6% of the theoretical butyrate content of TB. Interestingly, co-administration of Limosilactobacillus reuteri ATCC 53608 (REU) and Lacticaseibacillus rhamnosus ATCC 53103 (LGG) markedly enhanced butyrate to levels that exceeded the theoretical butyrate content of TB (138 ± 11% for REU; 126 ± 8% for LGG). Both TB + REU and TB + LGG stimulated Coprococcus catus, a lactate-utilizing, butyrate-producing species. The stimulation of C. catus with TB + REU was remarkably consistent across the six human adults tested. It is hypothesized that LGG and REU ferment the glycerol backbone of TB to produce lactate, a precursor of butyrate. TB + REU also significantly stimulated the butyrate-producing Eubacterium rectale and Gemmiger formicilis and promoted microbial diversity. The more potent effects of REU could be due to its ability to convert glycerol to reuterin, an antimicrobial compound. Overall, both the direct butyrate release from TB and the additional butyrate production via REU/LGG-mediated cross-feeding were highly consistent. This contrasts with the large interpersonal differences in butyrate production that are often observed upon prebiotic treatment. Combining TB with LGG and especially REU is thus a promising strategy to consistently supply butyrate to the host, potentially resulting in more predictable health benefits.
format Online
Article
Text
id pubmed-10054277
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100542772023-03-30 Lacticaseibacillus rhamnosus ATCC 53103 and Limosilactobacillus reuteri ATCC 53608 Synergistically Boost Butyrate Levels upon Tributyrin Administration Ex Vivo Van den Abbeele, Pieter Goggans, Mallory Deyaert, Stef Baudot, Aurélien Van de Vliet, Michiel Calatayud Arroyo, Marta Lelah, Michael Int J Mol Sci Article Modulation of the gut microbiota is a trending strategy to improve health. While butyrate has been identified as a key health-related microbial metabolite, managing its supply to the host remains challenging. Therefore, this study investigated the potential to manage butyrate supply via tributyrin oil supplementation (TB; glycerol with three butyrate molecules) using the ex vivo SIFR(®) (Systemic Intestinal Fermentation Research) technology, a highly reproducible, in vivo predictive gut model that accurately preserves in vivo-derived microbiota and enables addressing interpersonal differences. Dosing 1 g TB/L significantly increased butyrate with 4.1 (±0.3) mM, corresponding with 83 ± 6% of the theoretical butyrate content of TB. Interestingly, co-administration of Limosilactobacillus reuteri ATCC 53608 (REU) and Lacticaseibacillus rhamnosus ATCC 53103 (LGG) markedly enhanced butyrate to levels that exceeded the theoretical butyrate content of TB (138 ± 11% for REU; 126 ± 8% for LGG). Both TB + REU and TB + LGG stimulated Coprococcus catus, a lactate-utilizing, butyrate-producing species. The stimulation of C. catus with TB + REU was remarkably consistent across the six human adults tested. It is hypothesized that LGG and REU ferment the glycerol backbone of TB to produce lactate, a precursor of butyrate. TB + REU also significantly stimulated the butyrate-producing Eubacterium rectale and Gemmiger formicilis and promoted microbial diversity. The more potent effects of REU could be due to its ability to convert glycerol to reuterin, an antimicrobial compound. Overall, both the direct butyrate release from TB and the additional butyrate production via REU/LGG-mediated cross-feeding were highly consistent. This contrasts with the large interpersonal differences in butyrate production that are often observed upon prebiotic treatment. Combining TB with LGG and especially REU is thus a promising strategy to consistently supply butyrate to the host, potentially resulting in more predictable health benefits. MDPI 2023-03-20 /pmc/articles/PMC10054277/ /pubmed/36982942 http://dx.doi.org/10.3390/ijms24065859 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Van den Abbeele, Pieter
Goggans, Mallory
Deyaert, Stef
Baudot, Aurélien
Van de Vliet, Michiel
Calatayud Arroyo, Marta
Lelah, Michael
Lacticaseibacillus rhamnosus ATCC 53103 and Limosilactobacillus reuteri ATCC 53608 Synergistically Boost Butyrate Levels upon Tributyrin Administration Ex Vivo
title Lacticaseibacillus rhamnosus ATCC 53103 and Limosilactobacillus reuteri ATCC 53608 Synergistically Boost Butyrate Levels upon Tributyrin Administration Ex Vivo
title_full Lacticaseibacillus rhamnosus ATCC 53103 and Limosilactobacillus reuteri ATCC 53608 Synergistically Boost Butyrate Levels upon Tributyrin Administration Ex Vivo
title_fullStr Lacticaseibacillus rhamnosus ATCC 53103 and Limosilactobacillus reuteri ATCC 53608 Synergistically Boost Butyrate Levels upon Tributyrin Administration Ex Vivo
title_full_unstemmed Lacticaseibacillus rhamnosus ATCC 53103 and Limosilactobacillus reuteri ATCC 53608 Synergistically Boost Butyrate Levels upon Tributyrin Administration Ex Vivo
title_short Lacticaseibacillus rhamnosus ATCC 53103 and Limosilactobacillus reuteri ATCC 53608 Synergistically Boost Butyrate Levels upon Tributyrin Administration Ex Vivo
title_sort lacticaseibacillus rhamnosus atcc 53103 and limosilactobacillus reuteri atcc 53608 synergistically boost butyrate levels upon tributyrin administration ex vivo
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054277/
https://www.ncbi.nlm.nih.gov/pubmed/36982942
http://dx.doi.org/10.3390/ijms24065859
work_keys_str_mv AT vandenabbeelepieter lacticaseibacillusrhamnosusatcc53103andlimosilactobacillusreuteriatcc53608synergisticallyboostbutyratelevelsupontributyrinadministrationexvivo
AT goggansmallory lacticaseibacillusrhamnosusatcc53103andlimosilactobacillusreuteriatcc53608synergisticallyboostbutyratelevelsupontributyrinadministrationexvivo
AT deyaertstef lacticaseibacillusrhamnosusatcc53103andlimosilactobacillusreuteriatcc53608synergisticallyboostbutyratelevelsupontributyrinadministrationexvivo
AT baudotaurelien lacticaseibacillusrhamnosusatcc53103andlimosilactobacillusreuteriatcc53608synergisticallyboostbutyratelevelsupontributyrinadministrationexvivo
AT vandevlietmichiel lacticaseibacillusrhamnosusatcc53103andlimosilactobacillusreuteriatcc53608synergisticallyboostbutyratelevelsupontributyrinadministrationexvivo
AT calatayudarroyomarta lacticaseibacillusrhamnosusatcc53103andlimosilactobacillusreuteriatcc53608synergisticallyboostbutyratelevelsupontributyrinadministrationexvivo
AT lelahmichael lacticaseibacillusrhamnosusatcc53103andlimosilactobacillusreuteriatcc53608synergisticallyboostbutyratelevelsupontributyrinadministrationexvivo